GLP-1 drugs like semaglutide and tirzepatide may no longer face the same federal shortages that reshaped the market in recent years, but a new investigation suggests the demand for compounded versions has not faded. Researchers at the University of Colorado Anschutz report that many weight-loss clinics and medical spas continue selling compounded GLP-1 products even after the FDA resumed enforcement against routine copies of commercially available drugs.
The study, published in JAMA Health Forum, used a “secret shopper” design to probe how these medications are marketed and sourced in the real world, focusing on brick-and-mortar practices rather than online telehealth. Investigators contacted businesses in Oklahoma and West Virginia to ask what compounded products were offered, how patients were monitored, and where the active ingredients were obtained.
Rather than disappearing, the compounded GLP-1 channel appears to have persisted in a diffuse form. Investigators identified 75 clinics and medical spas that advertised compounded GLP-1 medications. Importantly, the team observed patterns indicating that some compounded products now include added ingredients—such as vitamin B12—that may be described as individualized formulations.
From a technical standpoint, this raises a question about the boundary between legitimate pharmacy customization and marketing-driven “personalization.” The researchers note that while compounding can sometimes be clinically justified, many added ingredients have limited evidence for improving safety, efficacy, or metabolic outcomes in the context of GLP-1 therapy.
Supply-chain scrutiny further complicated the picture. Among 23 compounding pharmacies supplying these businesses, four lacked licenses required for sterile compounding. The researchers also found that several suppliers had recent disciplinary actions or FDA warning letters tied to sterile compounding practices.
The study did not directly test whether the compounded medications are clinically unsafe or effective. Instead, it evaluated regulatory and sourcing signals, mapping where risk might concentrate when enforcement and quality verification are harder to oversee across many small entities.
Lead author Michael J. DiStefano, PhD, MBE, argues that patients should not have to trade affordability for confidence in manufacturing standards. He suggests regulatory innovation may be needed to preserve access while improving transparency—especially as the market remains large and geographically scattered.
For patients, the practical takeaway is to ask more detailed questions about compounding origins, sterile preparation credentials, and monitoring protocols. The researchers hope their findings will encourage both clinicians and consumers to treat sourcing and governance as part of effective obesity pharmacotherapy.
-
Subject of Research
-
Compounded GLP-1 weight-loss medications (semaglutide, tirzepatide) regulation and sourcing by clinics and compounding pharmacies
Article Title: (Not provided)
News Publication Date: 17-Jul-2026
Web References: https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.2207
References: DOI 10.1001/jamahealthforum.2026.2207 (as given)
Image Credits: (Not provided)
Keywords: GLP-1, compounded medications, semaglutide, tirzepatide, sterile compounding, FDA enforcement, weight-loss clinics, regulatory oversight, patient safety, JAMA Health Forum
